Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

A study by former Junior Associate Professor Kazuo Takayama, currently a professor of the Institute of Science Tokyo, ...

Respiratory syncytial virus–related complications and healthcare costs among a Medicare-insured population in the United States. Open Forum Infectious Diseases, 10(5), ofad203. https://doi.org ...

A study reveals that Respiratory Syncytial Virus-associated Acute Respiratory Infection increases death risk in adults. The risk is three times higher within a year. RSV can lead to ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides effective protection against respiratory syncytial virus-related lower ...

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...

RSV, or respiratory syncytial virus, is one of the leading causes of serious respiratory ill-health in the early years of one's life, and is usually prevalent during early winter months.

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in hospitalized infants under six months of age with respiratory syncytial virus.